

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		10/533,734	
				FILING DATE		May 4, 2005	
				APPLICANT		Ertl	
				GROUP		1648	
				EXAMINER		Kinsey	
				ATTORNEY DOCKET NO.		PG5023USw	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
		99/016884	08 April 1999	WO			
		02/099101	12 Dec 2002	WO			
		02/0220080	21 Mar 2002	WO			
		04/041851	21 May 2004	WO			
		1015596	30 Aug 2006	EP			
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
		Asjo et al., Phase 1 trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy, AIDS Res Hum Retroviruses 18(18):1357-1365 (Dec 2002)					
		Azad et al., Large-scale production and characterization of recombinant HIV-1 Nef, J. General Virology, 75:651-655 (1994)					
		Berzofsky, Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization, Biotechnol. Ther. 2(1-2): 123-135 (1991)					
		Betts et al., Optimal antigens for HIV vaccines based on CD8 + T response, protein length, and sequence variability, DNA Cell Biology 21(9):665-670 (Sept. 2002)					
		Cosma et al., Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals, Vaccine 22(1), 21-29 (Dec 2003)					
		Deml et al, Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein, J. Virology 75(22):10991-11001 (2001)					
		Estaquier et al., Comprehensive delineation of antigenic and immunogenic properties of peptides derived from the nef HIV-1 regulatory protein, Vaccine 11(11):1083-1092 (1993)					
		Gahery-Segard et al., Long term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+T cell epitopes recognized, J. Virol. 77(20):11220-11231 (Oct. 2003)					
		Gahery-Segard et al., Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine, J. Virol. 74(4):1694-1703 (Feb. 2000)					
		Hinkula et al., Recognition of prominent viral epitopes induced by immunization with HIV-1 regulatory genes, J. Virology, 71(7), 5528-5539 (1997)					
		Johnson and Walker, Cytotoxic T lymphocytes in human immunodeficiency virus infection: responses to structural protein, Curr Top Microbiol Immunol. 189:35-63 (1994)					
		Kmiecik et al., Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by G/P-92 fusion protein expressing highly immunogenic Gag P17/p24 and Pol p51 antigens, J Human Virology 4(6):306-316 (2001)					
		Letvin et al., Progress in the development of Nan HIV-1 Vaccine, Science 280:1875 (1998)					
		Pialoux et al., Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers, AIDS 15(10):1239-1249 (July 2001)					

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NK/

		Robert Guroff, HIV Regulatory and accessory proteins, new targets for vaccine development, DNA and Cell Biology, 21(9): 597-598 (Sept 2002)
		Zur Megede et al., Increased expression and immunogenicity of sequence modified HIV-1 gag gene, J. Virology 74:2628 (2000)
EXAMINER	/Nicole Kinsey/	DATE CONSIDERED 07/23/2009
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.		